Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium

Yu, Jiazheng; Wu, Siyu; Chen, Huafu; Jiang, Yuan‐Hong; Zheng, Jianyi; Li, Zeyu; Li, Mingyang; Xin, Kerong; Guan, Xiaojiao; Li, Shijie; Chen, Xiaonan

doi:10.1186/s13045-023-01475-9

Cited by 6 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, ADC agents have showcased compelling efficacy and survival advantages for patients with la/ mUC [102,103]. In a phase II clinical study (RC48-C005), 43 patients with HER2-positive la/mUC that had progressed after at least one prior systemic chemotherapy were enrolled.…”

Section: Disitamab Vedotin (Rc48)mentioning

confidence: 99%

A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers

Liu,

Li,

et al. 2024

Mol Cancer

View full text Add to dashboard Cite

While strategies such as chemotherapy and immunotherapy have become the first-line standard therapies for patients with advanced or metastatic cancer, acquired resistance is still inevitable in most cases. The introduction of antibody‒drug conjugates (ADCs) provides a novel alternative. ADCs are a new class of anticancer drugs comprising the coupling of antitumor mAbs with cytotoxic drugs. Compared with chemotherapeutic drugs, ADCs have the advantages of good tolerance, accurate target recognition, and small effects on noncancerous cells. ADCs occupy an increasingly important position in the therapeutic field. Currently, there are 13 Food and Drug Administration (FDA)‒approved ADCs and more than 100 ADC drugs at different stages of clinical trials. This review briefly describes the efficacy and safety of FDA-approved ADCs, and discusses the related problems and challenges to provide a reference for clinical work.

show abstract

Section: Disitamab Vedotin (Rc48)mentioning

confidence: 99%

A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers

Liu,

Li,

et al. 2024

Mol Cancer

View full text Add to dashboard Cite

show abstract

“…In terms of safety, overall, 55.9% of the patients in the EV plus P arm experienced grade 3 or greater TRAEs compared to 69.5% of those patients treated with chemotherapy. The common grade 3 and 4 side effects were a maculopapular rash (7.7%), hyperglycemia (5.0%), and neutropenia (4.8%) in the EV + P arm, and hematologic toxicities for the chemotherapy group, including anemia (31.4%), neutropenia (30.0%), and thrombocytopenia (19.4%) [2,38].…”

Section: Enfortumab Vedotinmentioning

confidence: 99%

Antibody–Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data

Nathan,

Rajeh,

Noor

et al. 2024

Current Oncology

View full text Add to dashboard Cite

The treatment landscape of genitourinary cancers has significantly evolved over the past few years. Renal cell carcinoma, bladder cancer, and prostate cancer are the most common genitourinary malignancies. Recent advancements have produced new targeted therapies, particularly antibody–drug conjugates (ADCs), due to a better understanding of the underlying oncogenic factors and molecular mechanisms involved. ADCs function as a ‘drug delivery into the tumor’ system. They are composed of an antigen-directed antibody linked to a cytotoxic drug that releases cytotoxic components after binding to the tumor cell’s surface antigen. ADCs have been proven to be extremely promising in the treatment of several cancer types. For GU cancers, this novel treatment has only benefited patients with metastatic urothelial cancer (mUC). The rest of the GU cancer paradigm does not have any FDA-approved ADC treatment options available yet. In this study, we have thoroughly completed a narrative review of the current literature and summarized preclinical studies and clinical trials that evaluated the utility, activity, and toxicity of ADCs in GU cancers, the prospects of ADC development, and the ongoing clinical trials. Prospective clinical trials, retrospective studies, case reports, and scoping reviews were included.

show abstract

“…Although EV has shown significant efficacy, the high incidence of peripheral neurotoxicity and severe cutaneous toxicity after intravenous administration has been linked to its use in first-line patients [93]. However, the local exposure characteristics of intravesical therapy significantly reduce the systemic exposure dose, which may open up new possibilities for EV in the treatment of NMIBC [94].…”

Section: Monotherapy or Combination Therapy In Ucmentioning

confidence: 99%

The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies

Yu,

Zhu,

You

et al. 2024

Cell Death Dis

View full text Add to dashboard Cite

With the high incidence of urogenital tumors worldwide, urinary system tumors are among the top 10 most common tumors in men, with prostate cancer ranking first and bladder cancer fourth. Patients with resistant urogenital tumors often have poor prognosis. In recent years, researchers have discovered numerous specific cancer antigens, which has led to the development of several new anti-cancer drugs. Using protein analysis techniques, researchers developed immune checkpoint inhibitors (ICIs) and antibody-conjugated drugs (ADCs) for the treatment of advanced urogenital tumors. However, tumor resistance often leads to the failure of monotherapy. Therefore, clinical trials of the combination of ICIs and ADCs have been carried out in numerous centers around the world. This article reviewed phase 2 and 3 clinical studies of ICIs, ADCs, and their combination in the treatment of urogenital tumors to highlight safe and effective methods for selecting individualized therapeutic strategies for patients. ICIs activate the immune system, whereas ADCs link monoclonal antibodies to toxins, which can achieve a synergistic effect when the two drugs are combined. This synergistic effect provides multiple advantages for the treatment of urogenital tumors.

show abstract

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium

Cited by 6 publications

References 11 publications

A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers

A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers

Antibody–Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data

The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies

Contact Info

Product

Resources

About